Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma
Anticancer Research · 2025
DOI: 10.21873/anticanres.17552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Akifumi Kuwano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bilirubin, Antineoplastic Combined Chemotherapy Protocols.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com.
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
Zitieren
APA
Kuwano, A., Yada, M., Tanaka, K., Takahira, J., Suzuki, H., & Motomura, K. (2025). Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17552
Vancouver
Kuwano A, Yada M, Tanaka K, Takahira J, Suzuki H, Motomura K. Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17552
BibTeX
@article{Kuwano2025,
author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Takahira, Junro and Suzuki, Hideo and Motomura, Kenta},
title = {Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17552}
}
EUVIMED